British National Formulary

Last updated

British National Formulary (BNF)
BNF 73 cover image.jpg
The cover of BNF 73 (March 2017)
AuthorPharmaceutical Press, the Royal Pharmaceutical Society's knowledge business
Language British English
Subject Medicine, Pharmacy
GenreMedicines Information
Publisher BMJ and
Pharmaceutical Press
Publication date
September 2022 (84th edition)
Publication placeUnited Kingdom
Media typePaperback print, digital online, smartphone app
Pages1,844
ISBN 978-0-85711-432-7
OCLC 1338666044
Website www.bnf.org

The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS). Information within the BNF includes indication(s), contraindications, side effects, doses, legal classification, names and prices of available proprietary and generic formulations, and any other notable points. [1] Though it is a national formulary, it nevertheless also includes entries for some medicines which are not available under the NHS, and must be prescribed and/or purchased privately. A symbol clearly denotes such drugs in their entry.

Contents

It is used by pharmacists and doctors (both general practitioners (GPs) and generalist hospital practitioners, and by other prescribing healthcare professionals (such as nurses, pharmacy technicians, paramedics, and dentists)); as a reference for correct dosage, indication, interactions and side effects of drugs. It is also used as a reassurance by those administering drugs, for example a nurse on a hospital ward, and even for patients and others seeking an authoritative source of advice on any aspect of pharmacotherapy.

Development

Many individuals and organisations contribute towards the preparation of the BNF. It is authored by Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business; and is jointly published by the BMJ (owned by the BMA), and Pharmaceutical Press (owned by the RPS). It is published under the authority of a Joint Formulary Committee (JFC), [2] which comprises pharmacy, medical, nursing, and lay representatives; there are also representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Health Departments, and a national guideline producer.

Information on drugs is drawn from the manufacturers' product literature, medical and pharmaceutical literature, regulatory authorities and professional bodies. Advice is constructed from clinical literature, and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the Joint Formulary Committee takes advice on all therapeutic areas from advisers from expert groups; this ensures that the BNF's recommendations are relevant to practice. In September 2016, the National Institute for Health and Care Excellence (NICE) in the UK gave NICE accreditation to the processes to produce BNF publications; a further review in 2021 resulted in the successful renewal of accreditation. [3]

History

It was first published in 1949, [2] as the National Formulary, with updated versions appearing every three years until 1976. The fifth version in 1957 saw its name change to The British National Formulary. [4] [5] A new-look version, under the auspices of Owen Wade, was released in 1981. [2] [6] A study in Northern Ireland, looking at prescribing in 1965, reported that the BNF was likely able to serve the requirements of prescribers in general practice, while also achieving a cost saving. [7] By 2003, issue 46 of the BNF contained 3000 interactions or groups of interactions, with about 900 of these marked by a bullet. [8] [9] [10] [11] [12]

Editions

A new edition of the BNF book is published twice-yearly, in March and September. [1] The current edition is 87, which was published in March 2024. It is a tradition that the colour of each new edition is radically different from the previous. [2]

Availability

The BNF is presently available as a book, a website, and mobile applications - the latter for use on smartphones and tablets. [2] The book is available for purchase, and the September edition is distributed to healthcare professionals in the UK at no direct cost to them. [1] [13] NHS workers and healthcare professionals in the HINARI group of developing nations are entitled to free access via MedicinesComplete following registration (requires provision of a name, an address, an email address, and a phone number). Other visitors can subscribe to the BNF on MedicinesComplete. [14] Healthcare organisations can also subscribe to a customisable BNF via their corporate online intranet. [15] In 2017, BNF Publications released applications for offline access to the BNF on iOS and Android devices. Monthly content updates are available, over an internet connection. [16] NICE provides a website providing the content of the BNF to the public, including non-NHS users. [17]

The BNF also includes the Nurse Prescribers' Formulary (NPF) and other NPF content for use by District Nurses and Specialist Community Public Health Nurses (including Health Visitors), who have received training to become nurse prescribers. [18]

Sister publications

The British National Formulary for Children (BNFC) [1] [19] [20] book, first published September 2005, [2] is published yearly, [2] and details the doses and uses of medicines in children from neonates to adolescents. [1]

BNF sections

The British National Formulary is divided into various sections; with the main sections on drugs and preparations being organised by body system.

Table of Contents
Notes on drugs and preparations
  1. Gastro-intestinal system
  2. Cardiovascular system
  3. Respiratory system
  4. Nervous system
  5. Infection
  6. Endocrine system
  7. Genito-urinary system
  8. Malignant disease
  9. Blood and nutrition
  10. Musculoskeletal system
  11. Eye
  12. Ear, nose, and oropharynx
  13. Skin
  14. Vaccines
  15. Anaesthesia
  16. Emergency treatment of poisoning
Appendices and indices

See also

Related Research Articles

<span class="mw-page-title-main">Medical prescription</span> Health-care communication from a physician to a pharmacist

A prescription, often abbreviated or Rx, is a formal communication from a physician or other registered healthcare professional to a pharmacist, authorizing them to dispense a specific prescription drug for a specific patient. Historically, it was a physician's instruction to an apothecary listing the materials to be compounded into a treatment—the symbol ℞ comes from the first word of a medieval prescription, Latin recipere, that gave the list of the materials to be compounded.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk.

<span class="mw-page-title-main">Prochlorperazine</span> Medication for nausea, psychosis, and anxiety

Prochlorperazine, formerly sold under the brand name Compazine among others, is a medication used to treat nausea, migraines, schizophrenia, psychosis and anxiety. It is a less preferred medication for anxiety. It may be taken by mouth, rectally, injection into a vein, or injection into a muscle.

<span class="mw-page-title-main">Tizanidine</span> Muscle relaxant medication

Tizanidine, sold under the brand name Zanaflex among others, is an alpha-2 (α2) adrenergic receptor agonist, similar to clonidine, that is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Effectiveness appears similar to baclofen or diazepam. It is taken by mouth.

<i>British National Formulary for Children</i>

BNF for Children (BNFC) is the standard UK paediatric reference for prescribing and pharmacology.

<span class="mw-page-title-main">Triptorelin</span> GnRH-agonist

Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Pharmaceutical policy is a branch of health policy that deals with the development, provision and use of medications within a health care system. It embraces drugs, biologics, vaccines and natural health products.

A formulary is a list of pharmaceutical drugs, often decided upon by a group of people, for various reasons such as insurance coverage or use at a medical facility. Traditionally, a formulary contained a collection of formulas for the compounding and testing of medication. Today, the main function of a prescription formulary is to specify particular medications that are approved to be prescribed at a particular hospital, in a particular health system, or under a particular health insurance policy. The development of prescription formularies is based on evaluations of efficacy, safety, and cost-effectiveness of drugs.

Electronic prescription is the computer-based electronic generation, transmission, and filling of a medical prescription, taking the place of paper and faxed prescriptions. E-prescribing allows a physician, physician assistant, pharmacist, or nurse practitioner to use digital prescription software to electronically transmit a new prescription or renewal authorization to a community or mail-order pharmacy. It outlines the ability to send error-free, accurate, and understandable prescriptions electronically from the healthcare provider to the pharmacy. E-prescribing is meant to reduce the risks associated with traditional prescription script writing. It is also one of the major reasons for the push for electronic medical records. By sharing medical prescription information, e-prescribing seeks to connect the patient's team of healthcare providers to facilitate knowledgeable decision making.

Karol Sikora is a British physician specialising in oncology, who has been described as a leading world authority on cancer. He was a founder and medical director of Rutherford Health, a company that provided proton therapy services, and is Director of Medical Oncology at the Bahamas Cancer Centre.

<span class="mw-page-title-main">Michael Rawlins</span> British clinical pharmacologist (1941–2023)

Sir Michael David Rawlins was a British clinical pharmacologist and emeritus professor at the University of Newcastle upon Tyne. During his medical career he chaired several executive agencies including the Committee on Safety of Medicines from 1993 to 1998, followed by the National Institute for Health and Care Excellence (NICE) for 14 years from its formation in 1999 and then the Medicines and Healthcare products Regulatory Agency (MHRA) for six years from 2014. From 2012 to 2014 he was president of the Royal Society of Medicine.

<i>Irish Medicines Formulary</i>

Irish Medicines Formulary (IMF) is a medicines reference for doctors, nurses, pharmacists and dentists, providing medicines information which is medico-legally relevant in Ireland. It is published in online and print formats, and lists original brands, branded generics and pure generic prescription medicines.

Covert medication, the covert administration of medicines is when medicines are administered in a disguised form, usually in food or drink, without the knowledge or consent of the individual receiving the drug. The decision-making processes surrounding covert medication should be in the best interests of the patient, transparent and inclusive.

<span class="mw-page-title-main">Lumacaftor/ivacaftor</span> Cystic fibrosis drug

Lumacaftor/ivacaftor, sold under the brand name Orkambi among others, is a combination of lumacaftor and ivacaftor used to treat people with cystic fibrosis who have two copies of the F508del mutation. It is unclear if it is useful in cystic fibrosis due to other causes. It is taken by mouth.

Joseph Gavin Collier is a British retired clinical pharmacologist and emeritus professor of medicines policy at St George's Hospital and Medical School in London, whose early research included establishing the effect of aspirin on human prostaglandins and looking at the role of nitric oxide and angiotensin converting enzyme in controlling blood vessel tone and blood pressure. Later, in his national policy work, he helped change the way drugs are priced and bought by the NHS, and ensured that members of governmental advisory committees published their conflicts of interest.

Azeem Majeed is a Professor and Head of the Department of Primary Care & Public Health at Imperial College, London, as well as a general practitioner in South London and a consultant in public health. In the most recent UK University Research Excellence Framework results, Imperial College London was the highest ranked university in the UK for the quality of research in the “Public Health, Health Services and Primary Care” unit of assessment.

Emma Harriet Baker is a British professor of clinical pharmacology and consultant physician in internal medicine at St George's Hospital, London. She has a specialist interest in people who have multiple medical conditions at the same time and take several medications, with a particular focus on lung disease. She is director of the UK's first BSc in clinical pharmacology, clinical vice president of the British Pharmacological Society and training programme director at Health Education England.

<i>The Top 100 Drugs</i> 21st-century book about pharmacology

The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing is a pocket-size medical manual focusing on the most commonly prescribed medicines by the British National Health Service (NHS). It was first published by Churchill Livingstone, Elsevier, in 2014, revised in a second edition in 2018, and again in 2022 in a third edition. It is authored by four clinical pharmacologists from St George's Hospital, London; Andrew Hitchings, Dagan Lonsdale, Daniel Burrage and Emma Baker.

References

  1. 1 2 3 4 5 "BNF Publications - Books". www.bnf.org. BMJ Group and Royal Pharmaceutical Society. Archived from the original on 17 August 2016. Retrieved 16 August 2016.
  2. 1 2 3 4 5 6 7 "BNF Publications - About - Our organisation". www.bnf.org. BMJ Group and Royal Pharmaceutical Society. Archived from the original on 17 August 2016. Retrieved 16 August 2016.
  3. "Accreditation decisions". NICE. September 2021. Retrieved 9 January 2023.
  4. Anon (1957). "The British National Formulary". British Medical Journal . 2 (5047): 758–759. PMC   1962234 . PMID   13460381.
  5. Wade, O. L. (1993). "British National Formulary: Its birth, death, and rebirth". BMJ (Clinical Research Ed.). 306 (6884): 1051–1054. doi:10.1136/bmj.306.6884.1051. PMC   1676980 . PMID   8490505.
  6. Anon (1978). "British National Formulary 1976-8". British Medical Journal . 2 (6136): 580–581. doi:10.1136/bmj.2.6136.580-b. PMC   1606955 . PMID   20792725.
  7. Wade, O. L.; McDevitt, G. D. (1966). "Prescribing and the British National Formulary". British Medical Journal . 2 (5514): 635–637. doi:10.1136/bmj.2.5514.635. PMC   1943465 . PMID   20791099.
  8. Aronson, J. K. (2004). "Drug interactions-information, education, and the British National Formulary". British Journal of Clinical Pharmacology . 57 (4): 371–372. doi:10.1111/j.1365-2125.2004.02125.x. PMC   1884473 . PMID   15025733.
  9. VNRAS.com, BNF 73. "BNF 73" (PDF). Archived (PDF) from the original on 21 October 2021.{{cite web}}: CS1 maint: numeric names: authors list (link)
  10. VNRAS.com. "BNF for Children BNFC 2019-2020" (PDF). Archived from the original (PDF) on 11 October 2021. Retrieved 1 May 2022.
  11. "BNF 78" (PDF).
  12. "BNF for Children BNFC 2019-2020" (PDF). Archived from the original (PDF) on 11 October 2021. Retrieved 1 May 2022.
  13. "BNF - NHS Evidence - Search Engine for Evidence in Health and Social Care". Archived from the original on 1 October 2012. Retrieved 2012-06-14.
  14. "Digital Medicines Information Suite". Archived from the original on 19 December 2008. Retrieved 22 December 2008. MedicinesComplete
  15. "BNF FormularyComplete". Archived from the original on 25 September 2011. BNF on FormularyComplete
  16. "NICE apps for smartphones and tablets". www.nice.org.uk. National Institute for Health and Care Excellence. April 2014. Archived from the original on 13 August 2014. Retrieved 19 July 2014.
  17. "BNF (British National Formulary" . nice.org.uk. Retrieved 4 August 2023.
  18. "BNF is only available in the UK". NICE. Retrieved 9 November 2023.
  19. Elias-Jones, A.; Rylance, G. (2005). "The launch of the British National Formulary for Children". Archives of Disease in Childhood . 90 (10): 997–998. doi:10.1136/adc.2005.080366. PMC   1720111 . PMID   16177154.
  20. "BNFC.org". Archived from the original on 20 December 2007. Retrieved 2006-09-07. British National Formulary for Children